Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: Mechanisms and clinical implications

Carcinogenesis

Volumn 27, Issue 4, 2006, Pages 673-681

  Tabakin Fix, Yulia ^a   Azran, Inbal ^a   Schavinky Khrapunsky, Yana ^a   Levy, Oren ^a   Aboud, Mordechai ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53; TAX PROTEIN;

APOPTOSIS; CANCER SURVIVAL; CELL CYCLE; CELL IMMORTALIZATION; CELL TRANSFORMATION; CHROMOSOME ABERRATION; GENE MUTATION; GENOME; HUMAN; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; RETROVIRUS; REVIEW; T CELL LEUKEMIA; TREATMENT FAILURE; WILD TYPE;

CELL TRANSFORMATION, NEOPLASTIC; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE PRODUCTS, TAX; GENES, P53; HUMANS; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645291496     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi274     Document Type: Review

References (155)

1. Suzuki,Y. and Gojobori,T. (1998) The origin and evolution of human T-cell lymphotropic virus types I and II. Virus Genes, 16, 69-84.
2. Vandamme,A.-M., Salemi,M. and Desmyter,J. (1998) The simian origins of the pathogenic human T-cell lymphotropic virus type I. Trends Microbiol., 6, 477-483.
3. Morgan,D.A., Ruscetti,F.W. and Gallo,R. (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science, 193, 1007-1008.
4. Ruscetti,F.W., Morgan,D.A. and Gallo,R.C. (1977) Functional and morphologic characterization of human T cells continuously grown in vitro. J. Immunol., 119, 131-138.
5. Gootenberg,J.E., Ruscetti,F.W., Mier,J.W., Gazdar,A. and Gallo,R.C. (1981) Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J. Exp. Med., 154, 1403-1418.
6. Mier,J.W. and Gallo,R.C. (1982) The purification and properties of human T cell growth factor. J. Immunol., 128, 1122-1127.
7. Poiesz,B.J., Ruscetti,F.W., Gazdar,A.F., Bunn,P.A., Minna,J.D. and Gallo,R.C. (1980) Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl Acad. Sci. USA, 77, 7415-7419.
8. Yoshida,M., Miyoshi,I. and Hinuma,Y. (1982) Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc. Natl Acad. Sci. USA, 79, 2031-2035.
9. Uchiyama,T., Yodoi,J., Sagawa,K., Takatsuki,K. and Uchino,H. (1977) Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood, 50, 481-492.
10. Takatsuki,K., Uchiyama,T. and Yodoi,J. (1977) Adult T-cell leukemia in Japan. In: Topics in Hematology. Excerpta Medic, Amsterdam.
11. Gessain,A., Barin,F., Vernant,J.C., Gout,O., Maurs,L., Calender,A. and de The,G. (1985) Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet, 2, 407-410.
12. Osame,M., Usuku,K., Izumo,S., Ijichi,N., Amitani,H., Igata,A., Matsumoto,M. and Tara,M. (1986) HTLV-I associated myelopathy, a new clinical entity. Lancet, 1, 1031-1032.
13. Proietti,F.A., Carneiro-Proietti,A.B., Catalan-Soares,B.C. and Murphy,E.L. (2005) Global epidemiology of HTLV-I infection and associated diseases. Oncogene, 24, 6058-6068.
14. Carvalho,E.M. and Da Fonseca Porto,A. (2004) Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol., 26, 487-497.
15. Azran,I., Schavinsky-Khrapunsky,Y., Priel,E., Huleihel,M. and Aboud,M. (2004) Implications of the evolution pattern of human T-cell leukemia retroviruses on their pathogenic virulence (Review). Int. J. Mol. Med., 14, 909-915.
16. Azran,I., Schavinsky-Khrapunsky,Y. and Aboud,M. (2004) Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology, 1, 20-43.
17. Jeang,K.T., Giam,C.Z., Majone,F. and Aboud,M. (2004) Life, death and Tax: Role of HTLV-1 oncoprotein in genetic instability and cellular transformation. J. Biol. Chem., 279, 31991-31994.
18. Taylor,G.P. and Matsuoka,M. (2005) Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene, 24, 6047-6057.
19. Matsuoka,M. (2005) Human T-cell leukemia virus type 1 (HTLV-1) infection and the onset of adult T-cell leukemia (ATL). Retrovirology, 2, 27-39.
20. Matsuoka,M. and Jeang,K.T. (2005) Human T-Cell leukemia virus type I at age 25: A, progress report. Cancer Res., 65, 4467-4470.
21. Takatsuki,K. (2005) Discovery of adult T-cell leukemia. Retrovirology, 2, 16-18.
22. Nicot,C. (2005) Current views in HTLV-I-associated adult T-cell leukemia/ lymphoma. Am. J. Hematol., 78, 232-239.
23. Yoshida,M. (2005) Discovery of HTLV-1, the first human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis. Oncogene, 24, 5931-5937.
24. Gallo,R.C. (2005) History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2. Oncogene, 24, 5926-5930.
25. Gallo,R.C. (2005) The discovery of the first human retrovirus: HTLV-1 and HTLV-2. Retrovirology, 2, 17-23.
26. Pise-Masison,C.A., Jeong,S.J. and Brady,J.N. (2005) Human T cell leukemia virus type 1: The role of Tax in leukemogenesis. Arch. Immunol. Ther. Exp. (Warsz), 53, 283-296.
27. Grassmann,R., Aboud,M. and Jeang,K.T. (2005) Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene, 24, 5976-5985.
28. Richardson,J.H., Edwards,A.J., Cruickshank,J.K., Rudge,P. and Dalgleish,A.G. (1990) In vivo cellular tropism of human T-cell leukemia virus type 1. J. Virol., 64, 5682-5687.
29. Newbound,G., Andrews,J., O'Rourke,J., Brady,J. and Lairmore,M. (1996) Human T-cell lymphotropic virus type 1 Tax mediates enhanced transcription in CD4+ T lymphocytes. J. Virol., 70, 2101-2106.
30. Copeland,K.F. and Heeney,J.L. (1996) T helper cell activation and human retroviral pathogenesis. Microbiol. Rev., 60, 722-742.
31. Pinsky,B.A. and Biggins,S. (2005) The spindle checkpoint: Tension versus attachment. Trends Cell Biol., 15, 486-493.
32. Iwanaga,Y., Kasai,T., Kibler,K. and Jeang,K.T. (2002) Characterization of regions in hsMAD1 needed for binding hsMAD2. A polymorphic changes in an hsMAD1 leucine zipper affects MAD1-MAD2 interaction and spindle checkpoint function. J. Biol. Chem., 277, 31005-31013.
33. Iwanaga,Y. and Jeang,K.T. (2002) Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by a gain-of-function p53 mutant. Cancer Res., 62, 2618-2624.
34. Kops,G.J., Weaver,B.A. and Cleveland,D.W. (2005) On the road to cancer: aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer, 5, 773-785.
35. Marriott,S.J., Lemoine,F.J. and Jeang,K.T. (2002) Damaged DNA and miscounted chromosomes: Human T cell leukemia virus type I tax oncoprotein and genetic lesions in transformed cells. J. Biomed. Sci., 9, 292-298.
36. Kasai,T., Iwanaga,Y., Iha,H. and Jeang,K.T. (2002) Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors. J. Biol. Chem., 277, 5187-5193.
37. Kamihira,S., Atogami,S., Sohda,H., Momita,S., Toryia,K., Ikeda,S., Yamada,Y. and Tomonaga,M. (1994) DNA aneuploidy of adult T-cell leukemia cells. Leuk. Res., 18, 79-84.
38. Marriott,S.J. and Semmes,O.J. (2005) Impact of HTLV-1 Tax on cell cycle progression and cellular DNA damage repair response. Oncogene, 24, 5986-5995.
39. Pise-Masison,C.A. and Brady,J.N. (2005) Setting the stage for transformation: HTLV-1 Tax inhibition of p53 function. Front. Biosci., 10, 919-930.
40. Stewart,Z.A. and Pietenpol,J.A. (2001) p53 Signaling and cell cycle checkpoints. Chem. Res. Toxicol., 14, 243-263.
41. Fridman,J.S. and Lowe,S.W. (2003) Control of apoptosis by p53. Oncogene, 22, 9030-9040.
42. Yu,J. and Zhang,L. (2005) The transcriptional targets of p53 in apoptosis control. Biochem. Biophys. Res. Commun., 331, 851-858.
43. Ford,J.M. (2005) Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53. Mutat. Res., 577, 195-202.
44. Arrowsmith,C.H. (1999) Structure and function in the p53 family. Cell Death Differ., 6, 1169-1173.
45. Torgeman,A., Mor-Vaknin,N., Zelin,E., Ben-Aroya,Z., Lochelt,M., Flugel,R.M. and Aboud,M. (2001) Sp1-p53 heterocomplex mediates activation of HTLV-I long terminal repeat by 12-O-tetradecanoylphorbol-13-acetate that is antagonized by protein kinase C. Virology, 281, 10-20.
46. Abramovitch,S. and Werner,H. (2003) Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene. Horm. Metab. Res., 35, 758-762.
47. Koutsodontis,G., Vasilaki,E., Chou,W.C., Papakosta,P. and Kardassis,D. (2005) Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis. Biochem. J., 389, 443-455.
48. Ho,J. and Benchimol,S. (2003) Transcriptional repression mediated by the p53 tumor suppressor. Cell Death Differ., 19, 404-408.
49. Prives,C. and Hall,P.A. (1999) The p53 pathway. J. Pathol., 187, 112-126.
50. Ko,L.J. and Prives,C. (1996) p53: Puzzle and paradigm. Genes Dev., 10, 1054-1072.
51. Oren,M. (1999) Regulation of the p53 tumor suppressor protein. J. Biol. Chem., 274, 36031-36034.
52. Xu,Y. (2003) Regulation of p53 responses by post-translational modifications. Cell. Death Differ., 10, 400-403.
53. Brooks,C.L. and Gu,W. (2003) Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation. Curr. Opin. Cell Biol., 15, 164-171.
54. Shaw,P., Freeman,J., Bovey,R. and Iggo,R. (1996) Regulation of specific DNA binding by p53: Evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene, 12, 921-930.
55. Shieh,S.Y., Taya,Y. and Prives,C. (1999) DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J., 18, 1815-1823.
56. Bond,G.L., Hu,W. and Levine,A.J. (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets, 5, 3-8.
57. Brady,M., Vlatkovic,N. and Boyd,M.T. (2005) Regulation of p53 and MDM2 activity by MTBP. Mol. Cell. Biol., 25, 545-553.
58. Moll,U.M. and Petrenko,O. (2003) The MDM2-p53 interaction. Mol. Cancer Res., 1, 1001-1008.
59. Kubbutat,M.H., Iones,S.N. and Vousden,K.H. (1997) Regulation of p53 stability by MDM2. Nature, 387, 299-303.
60. Yang,Y., Li,C.C. and Weissman,A.M. (2004) Regulating the p53 system through ubiquitination. Oncogene, 23, 2096-2106.
61. Kussie,P.H., Gorina,S., Marechal,V., Elenbaas,B., Moreau,J., Levine,A.J. and Pavletich,N.P. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274, 948-953.
62. Wsierska-Gadek,J. and Horky,M. (2003) How the nucleolar sequestration of p53 protein or its interplayers contributes to its (re)-activation. Ann. NY Acad. Sci., 1010, 266-272.
63. Sherr,C.J. (2001) The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol., 2, 731-737.
64. Lowe,S.W. and Sherr,C.J. (2003) Tumor suppression by Ink4a-Arf: Progress and puzzles. Curr. Opin. Genet. Develop., 13, 77-83.
65. Asher,G., Lotem,J., Kama,R., Sachs,L. and Shaul,Y. (2002) MDM2 and ubiquitin-independent p53 proteosomal degradation regulated by NQO1. Proc. Natl Acad. Sci. USA, 99, 13125-13130.
66. Asher,G., Tsvetkov,P., Kahana,C. and Shaul,Y. (2005) A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev., 19, 316-321.
67. Shvarts,A., Steegenga,W.T., Riteco,N. et al. (1996) MDMX: A novel p53-binding protein with some functional properties of MDM2. EMBO J., 15, 5349-5357.
68. Marine,J.C. and Jochemsen,A.G. (2005) Mdmx as an essential regulator of p53 activity. Biochem. Biophys. Res. Commun., 331, 750-760.
69. Corcoran,C.A., He,Q., Huang,Y. and Sheikh,M.S. (2005) Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis. Oncogene, 24, 1634-1640.
70. Lu,X. (2005) p53: A heavily dictated dictator of life and death. Curr. Opin. Genet. Dev., 15, 27-33.
71. Saito,S.i., Yamaguchi,H., Higashimoto,Y., Chao,C., Xu,Y., Fornace,A.J. Jr, Appella,E. and Anderson,C.W. (2003) Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J. Biol. Chem., 278, 37536-37544.
72. Dohoney,K.M., Guillerm,C., Whiteford,C., Elbi,C., Lambert,P.F., Hager,G.L. and Brady,J.N. (2004) Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage. Oncogene, 23, 49-57.
73. Prives,C. and Manley,J.L. (2001) Why is p53 acetylated? Cell, 107, 815-818.
74. Dumaz,N. and Meek,D.W. (1999) Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J., 18, 7002-7010.
75. Sakaguchi,K., Herrera,J.E., Saito,S.i., Miki,T., Bustin,M., Vassilev,A., Anderson,C.W. and Appella,E. (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev., 12, 2831-2841.
76. Chen,L., Gilkes,D.M., Pan,Y., Lane,W.S. and Chen,J. (2005) ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J., 24, 3411-3422.
77. Okamoto,K., Kashima,K., Pereg,Y. et al. (2005) DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol. Cell. Biol., 25, 9608-9620.
78. Wiseman,A. (2005) p53 Protein is activated by Pin1: And also by Cu-SOD prion-like enzyme. Med. Hypotheses, 65, 32-34.
79. Jimenez,G.S., Khan,S.H., Stommel,J.M. and Wahl,G.M. (1999) p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene, 18, 7656-7665.
80. Gostissa,M., Hofmann,T.G., Will,H. and Del Sal,G. (2003) Regulation of p53 functions: Let's meet at the nuclear bodies. Curr. Opin. Cell. Biol., 15, 351-357.
81. Ho,J.W., Song,J.Z. and Leung,Y.K. (2005) Activation of p53 by specific agents in potential cancer therapy. Curr. Med. Chem. Anti-Cancer Agents, 5, 131-135.
82. Chene,P. (2001) Targeting p53 in cancer. Curr. Med. Chem. Anti-Cancer Agents, 1, 151-161.
83. Roth,J.A., Swisher,S.G. and Meyn,R.E. (1999) p53 tumor suppressor gene therapy for cancer. Oncology (Williston Park), 13(Suppl. 5), 148-154.
84. Chene,P. (2004) Inhibition of the p53-MDM2 interaction: Targeting a protein-protein interface. Mol. Cancer Res., 2, 20-28.
85. Chene,P. (2004) Inhibition of the p53-hdm2 interaction with low molecular weight compounds. Cell Cycle, 3, 460-461.
86. Vassilev,L.T., Vu,B.T., Graves,B. et al. (2004) In vivo activation of the p53 pathway by pmall-molecule antagonists of MDM2. Science, 303, 844-848.
87. Haupt,S. and Haupt,Y. (2004) Manipulation of the tumor suppressor p53 for potentiating cancer therapy. Semin. Cancer Biol., 14, 244-252.
88. Bykov,V.J., Selivanova,G. and Wiman,K.G. (2003) Small molecules that reactivate mutant p53. Eur. J. Cancer, 39, 1828-1834.
89. Issaeva,N., Friedler,A., Bozko,P., Wiman,K.G., Fersht,A.R. and Selivanova,G. (2003) Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc. Natl Acad. Sci. USA, 100, 13303-13307.
90. Roth,J., Lenz-Bauer,C., Contente,A., Lohr,K., Koch,P., Bernard,S. and Dobbelstein,M. (2003) Reactivation of mutant p53 by a one-hybrid adaptor protein. Cancer Res., 63, 3904-3908.
91. Wilson,D.R. (2002) Viral-mediated gene transfer for cancer treatment. Curr. Pharm. Biotechnol., 3, 151-164.
92. Pirollo,K.F., Xu,L. and Chang,E.H. (2000) Non-viral gene delivery for p53. Curr. Opin. Mol. Ther., 2, 168-175.
93. Anklesaria,P. (2000) Gene therapy: A molecular approach to cancer treatment. Curr. Opin. Mol. Ther., 2, 426-432.
94. Gjerset,R.A. and Mercola,D. (2000) Sensitization of tumors to chemotherapy through gene therapy. Adv. Exp. Med. Biol., 465, 273-291.
95. Collot-Teixeira,S., Bass,J., Denis,F. and Ranger-Rogez,S. (2004) Human tumor suppressor p53 and DNA viruses. Rev. Med. Virol. 14, 301-319.
96. Mahieux,R., Pise-Masison,C.A., Nicot,C., Green,P., Hall,W.W. and Brady,J.N. (2000) Inactivation of p53 by HTLV type 1 and HTLV type 2 Tax trans-activators. AIDS Res. Hum. Retroviruses, 16, 1677-1681.
97. Hatta,Y. and Koeffler,H.P. (2002) Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL). Leukemia, 16, 1069-1085.
98. Tawara,M., Hogerzeil,S.J., Yamada,Y., Takasaki,Y., Soda,H., Hasegawa,H., Murata,K., Ikeda,S., Imaizumi,Y. and Sugahara,K. (2005) Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma. Cancer Lett., In Press.
99. Newcomb,E.W. (1995) P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk. Lymphoma., 17, 211-221.
100. Takemoto,S., Trovato,R., Cereseto,A., Nicot,C., Kislyakova,T., Casareto,L., Waldmann,T., Torelli,G. and Franchini,G. (2000) p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14ARF-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. Blood, 95, 3939-3944.
101. Reid,R.L., Lindholm,P.F., Mireskandari,A., Dittmer,J. and Brady,J.N. (1993) Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I. Oncogene, 8, 3029-3036.
102. Cereseto,A., Diella,F., Mulloy,J., Cara,A., Michieli,P., Grassmann,R., Franchini,G. and Klotman,M. (1996) p53 functional impairment and high p21waf1/cip1 expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells. Blood, 88, 1551-1560.
103. Pise-Masison,C.A., Choi,K.S., Radonovich,M., Dittmer,J., Kim,S.J. and Brady,J.N. (1998) Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J. Virol., 72, 1165-1170.
104. Akagi,T., Ono,H., Tsuchida,N. and Shimotohno,K. (1997) Aberrant expression and function of p53 in T-cells immortalized by HTLV-I Tax1. FEBS. Lett., 406, 263-266.
105. Ariumi,Y., Kaida,A., Lin,J.Y., Hirota,M., Masui,O., Yamaoka,S., Taya,Y. and Shimotohno,K. (2000) HTLV-1 tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration. Oncogene, 19, 1491-1499.
106. Pise-Masison,C.A., Mahieux,R., Radonovich,M., Jiang,H. and Brady,J.N. (2001) Human T-lymphotropic virus type I Tax protein utilizes distinct pathways for p53 inhibition that are cell type-dependent. J. Biol. Chem., 276, 200-205.
107. Pise-Masison,C.A., Radonovich,M., Sakaguchi,K., Appella,E. and Brady,J.N. (1998) Phosphorylation of p53: A novel Pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells. J. Virol., 72, 6348-6355.
108. Gartenhaus,R.B. and Wang,P. (1995) Functional inactivation of wild-type p53 protein correlates with loss of IL-2 dependence in HTLV-I transformed human T lymphocytes. Leukemia, 9, 2082-2086.
109. Jeang,K.T. (2001) Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: Cellular signaling through NF-κB. Cytokine Growth Factor Rev., 12, 207-217.
110. Pise-Masison,C.A., Mahieux,R., Jiang,H., Ashcroft,M., Radonovich,M., Duvall,J., Guillerm,C. and Brady,J.N. (2000) Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-κB pathway and is dependent on p53 phosphorylation. Mol. Cell. Biol., 20, 3377-3386.
111. Lill,N.L., Grossman,S.R., Ginsberg,D., DeCaprio,J. and Livingston,D.M. (1997) Binding and modulation of p53 by p300/CBP coactivators. Nature, 387, 823-837.
112. Scolnick,D.M., Chehab,N.H., Stavridi,E.S., Lien,M.C., Caruso,L., Moran,E., Berger,S.L. and Halazonetis,T.D. (1997) CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res., 57, 3693-3696.
113. Van Orden,K., Giebler,H.A., Lemasson,I., Gonzales,M. and Nyborg,J.K. (1999) Binding of p53 to the KIX domain of CREB binding Protein. A potental link to human T-cell leukemia virus type1-associated leukmogenesis. J. Biol. Chem., 274, 26321-26328.
114. Grossman,S.R. (2001) p300/CBP/p53 interaction and regulation of the p53 response. Eur. J. Biochem., 268, 2773-2778.
115. Livengood,J.A., Scoggin,K.E.S., Van Orden,K., McBryant,S.J., Edayathumangalam,R.S., Laybourn,P.J. and Nyborg,J.K. (2002) p53 transcriptional activity is mediated through the SRC1-interacting domain of CBP/p300. J. Biol. Chem., 277, 9054-9061.
116. Ravi,R., Mookerjee,B., van Hensbergen,Y., Bedi,G.C., Giordano,A., El-Deiry,W.S., Fuchs,E.J. and Bedi,A. (1998) p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300. Cancer Res., 58, 4531-4536.
117. Wadgaonkar,R., Phelps,K.M., Haque,Z., Williams,A.J., Silverman,E.S. and Collins,T. (1999) CREB-binding protein is a nuclear integrator of nuclear factor-κB and p53 signaling. J. Biol. Chem., 274, 1879-1882.
118. Webster,G.A. and Perkins,N.D. (1999) Transcriptional cross talk between NF-κB and p53. Mol. Cell. Biol., 19, 3485-3495.
119. Ikeda,A., Sun,X, Li,Y., Zhang,Y., Eckner,R., Doi,T.S., Takahashi,T., Obata,Y., Yoshioka,K. and Yamamoto,K. (2000) p300/CBP-dependent and - independent transcriptional interference between NF-κB RelA and p53. Biochem. Biophys. Res. Commun., 272, 375-379.
120. Hellin,A.C., Calmant,P., Gielen,J., Bours,V. and Merville,M.P. (1998) Nuclear factor-kappaB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene, 16, 1187-1195.
121. Wu,H. and Lozano,G. (1994) NF-κB activation of p53. A potential mechanism for suppressing cell growth in response to stress. J. Biol. Chem., 269, 20067-20074.
122. Aleyasin,H., Cregan,S.P., Iyirhiaro,G., O'Hare,M.J., Callaghan,S.M., Slack,R.S. and Park,D.S. (2004) Nuclear factor-κB modulates the p53 response in neurons exposed to DNA damage. J. Neurosci., 24, 2963-2973.
123. Ryan,K.M., Ernst,M.K., Rice,N.R. and Vousden,K.H. (2000) Role of NF-κB in p53-mediated programmed cell death. Nature, 404, 892-897.
124. Jeong,S.J., Radonovich,M., Brady,J.N. and Pise-Masison,C.A. (2004) HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood, 104, 1490-1497.
125. Jeong,S.J., Pise-Masison,C.A., Radonovich,M.F., Park,H.U. and Brady,J.N. (2005) A novel NF-κB pathway involving IKKβ and p65/RelA Ser-536 phosphorylation results in p53 inhibition in the absence of NF-κB transcriptional activity. J. Biol. Chem., 280, 10326-10332.
126. Jeong,S.J., Pise-Masison,C.A., Radonovich,M.F., Park,H.U. and Brady,J.N. (2005) Activated AKT regulates NF-κB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene, 24, 6719-6728.
127. Coffer,P.J., Jin,J. and Woodgett,J.R. (1998) Protein kinase B (c-Akt): A multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem. J., 335, 1-13.
128. Kohn,K.W. and Pommier,Y. (2005) Molecular interaction map of the p53 and Mdm2 logic elements, which control the Off-On switch of p53 in response to DNA damage. Biochem. Biophys. Res. Commun., 331, 816-827.
129. Dreyfus,D.H., Nagasawa,M., Gelfand,E.W. and Ghoda,L.Y. (2005) Modulation of p53 activity by IkappaBalpha: Evidence suggesting a common phylogeny between NF-κB and p53 transcription factors. BMC Immunol., 6, 12.
130. Brown,K., Park,S., Kanno,T., Franzoso,G. and Siebenlist,U. (1993) Mutual regulation of the transcriptional activator NF-κB and its Inhibitor, IκBα. Proc. Natl Acad. Sci. USA, 90, 2532-2536.
131. Sun,S.C., Ganchi,P.A., Ballard,D.W. and Greene,W.C. (1993) NF-κB controls expression of inhibitor IκBα: Evidence for an inducible autoregulatory pathway. Science, 259, 1912-1915.
132. Yang,J.P., Hori,M., Takahashi,N., Kawabe,T., Kato,H. and Okamoto,T. (1999) NF-κB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. Oncogene, 18, 5177-5186.
133. Iwabuchi,K., Li,B., Massa,H.F., Trask,B.J., Date,T. and Fields,S. (1998) Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2. J. Biol. Chem., 273, 26061-26068.
134. Cao,Y., Hamada,T., Matsui,T., Date,T. and Iwabuchi,K. (2004) Hepatitis C virus core protein interacts with p53-binding protein, 53BP2/Bbp/ASPP2, and inhibits p53-mediated apoptosis. Biochem. Biophys. Res. Commun., 315, 788-795.
135. Miyazato,A., Sheleg,S., Iha,H., Li,Y. and Jeang,K.T. (2005) Evidence for NF-κB- and CBP-Independent repression of p53's transcriptional activity by human T-cell leukemia virus type 1 Tax in mouse embryo and primary human fibroblasts. J. Virol., 79, 9346-9350.
136. Mulloy,J.C., Kislyakova,T., Cereseto,A. et al. (1998) Human T-cell lymphotropic/leukemia virus type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through Its CREB/ATF functional domain. J. Virol., 72, 8852-8860.
137. Kalkhoven,E. (2004) CBP and p300: HATs for different occasions. Biochem. Pharmacol., 68, 1145-1155.
138. Chan,H.M. and La Thangue,N.B. (2001) p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell. Sci., 114, 2363-2373.
139. Van Orden,K. and Nyborg,J.K. (2000) Insight into the tumor suppressor function of CBP through the viral oncoprotein tax. Gene Expr., 9, 29-36.
140. Azran,I., Jeang,K.T. and Aboud,M. (2005) High levels of cytoplasmic HTLV-1 Tax mutant proteins retain a Tax-NF-kappaB-CBP ternary complex in the cytoplasm. Oncogene, 24, 4521-4530.
141. Vendel,A.C., McBryant,S.J. and Lumb,K.J. (2003) KIX-mediated assembly of the CBP-CREB-HTLV-1 tax coactivator-activator complex. Biochemistry, 42, 12481-12487.
142. Georges,S.A., Giebler,H.A., Cole,P.A., Luger,K., Laybourn,P.J. and Nyborg,J.K. (2003) Tax recruitment of CBP/p300, via the KIX domain, reveals a potent requirement for acetyltransferase activity that Is chromatin dependent and histone tail independent. Mol. Cell. Biol., 23, 3392-3404.
143. Scoggin,K.E.S., Ulloa,A. and Nyborg,J.K. (2001) The oncoprotein Tax binds the SRC-1-interacting domain of CBP/p300 to mediate transcriptional activation. Mol. Cell. Biol., 21, 5520-5530.
144. Harrod,R., Kuo,Y.L., Tang,Y., Yao,Y., Vassilev,A., Nakatani,Y. and Giam,C.Z. (2000) p300 and p300/cAMP-responsive element-binding protein associated factor interact with human T-cell lymphotropic virus type-1 Tax in a multi-histone acetyltransferase/activator-enhancer complex. J. Biol. Chem., 275, 11852-11857.
145. Jiang,H., Lu,H., Schiltz,R.L., Pise-Masison,C.A., Ogryzko,V.V., Nakatani,Y. and Brady,J.N. (1999) PCAF interacts with Tax and stimulates Tax transactivation in a histone acetyltransferase-independent manner. Mol. Cell. Biol., 19, 8136-8145.
146. Tabakin-Fix,Y., Huleihel,M. and Aboud,M. (2004) Activation of simian virus 40 promoter by HTLV-1 Tax protein: Role of NF-κB and CBP. Biocghem. Biophys. Res. Commun, 318, 1052-1056.
147. Van Orden,K., Yan,J.P., Ulloa,A. and Nyborg,J.K. (1999) Binding of the human T-cell leukemia virus Tax protein to the co-activator CBP interfers with CBP-mediated transcriptional control. Oncogene, 18, 3766-3772.
148. Lee,D.K., Kim,B.-C., Brady,J.N., Jeang,K.-T. and Kim,S.-J. (2002) Human T-cell lymphotropic virus type 1 Tax inhibits transforming growth factor-beta signaling by Blocking the association of Smad proteins with Smad-binding element. J. Biol. Chem., 277, 33766-33775.
149. Nicot,C., Mahieux,R., Pise-Masison,C., Brady,J., Gessain,A., Yamaoka,S. and Franchini,G. (2001) Human T-cell lymphotropic virus Type 1 Tax represses c-Myb-dependent transcription through activation of the NF-κB pathway and modulation of coactivator usage. Mol. Cell. Biol., 21, 7391-7402.
150. Lemasson,I. and Nyborg,J.K. (2001) Human T-cell leukemia virus type I Tax repression of p73β is mediated through competition for the C/H1 domain of CBP. J. Biol. Chem., 276, 15720-15727.
151. Mori,N., Morishita,M., Tsukazaki,T., Giam,C.Z., Kumatori,A., Tanaka,Y. and Yamamoto,N. (2001) Human T-cell leukemia virus type I oncoprotein Tax represses Smad-dependent transforming growth factor-β signaling through interaction with CREB-binding protein/p300. Blood, 97, 2137-2144.
152. Riou,P., Bex,F. and Gazzolo,L. (2000) The human T Cell leukemia/ lymphotropic virus type 1 Tax protein represses MyoD-dependent transcription by inhibiting MyoD-binding to the KIX domain of p300. A potential mechanism for Tax-mediated repression of the transcriptional activity of basic helix-loop-helix factors. J. Biol. Chem., 275, 10551-10560.
153. Suzuki,T., Uchida-Toita,M. and Yoshida,M. (1999) Tax protein of HTLV-1 inhibits CBP/p300-mediated transcription by interfering with recruitment of CBP/p300 onto DNA element of E-box or p53 binding site. Oncogene, 18, 4137-4143.
154. Chaudhry,S., Freebern,W.J., Smith,J.L., Butscher,W.G., Haggerty,C.M. and Gardner,K. (2002) Cross-regulation of T cell growth factor expression by p53 and the Tax oncogene. J. Immunol., 169, 6767-6778.
155. Meertens,L., Pise-Masison,C., Quere,N., Brady,J., Gessain,A. and Mahieux,R. (2004) Utilization of the CBP but not the p300 co-activator by human T-lymphotropic virus type-2 Tax for p53 inhibition. Oncogene, 23, 5447-5458.